Humana Inc vs Microsoft — how do they compare? Humana Inc trades at $444.98 (market cap $46.49B), while Microsoft trades at $527.96 (market cap $3.88T). The key difference: Microsoft is far larger — about 83.5× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Microsoft for 142 Days on average.
| HUM | MSFT | |
|---|---|---|
Market Cap | $46.49B | $3.88T |
Volume | 2,567,704 | 19,593,392 |
Sector | Health | Technology |
52-Week High | $409.85 | $542.07 |
52-Week Low | $163.67 | $352.83 |
Typical Hold Time | 53 Days | 142 Days |
Enterprise Value | $53.84B | $3.86T |
Dividend Yield | 0.91% | 0.75% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
Microsoft (MSFT) trades at $529.76, up 0.09% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 forecast. Revenue and net income have shown robust growth, reaching $281.72B and $101.83B in 2025, respectively. Analyst consensus is overwhelmingly positive, with 82% buy ratings and a $571.76 price target, indicating potential upside from current levels.
The outlook for MSFT remains favorable due to its leadership in AI and cloud computing, though risks include heightened capital expenditure concerns and competitive pressures. The stock's valuation multiples, such as a P/E of 29.51, reflect premium pricing but are supported by high profitability margins and growth prospects. Investors should weigh the strong institutional support against macroeconomic and sector-specific volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →